{
  "doc_id": "Relatório de avaliação de financiamento público de Lenvima (lenvatinib) 2020",
  "created_date": "2015",
  "country": "PT",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "Public RELATORIO DE AVALIAÇÃO LENVIMA is indicated as a monotherapy for the treatment of adult patients with advanced or non-resectable hepatocellular carcinoma (CHC), who have not received any prior systemic therapeutics.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "The following are the characteristics of the medicinal product:",
      "text": "DCI (common international denomination): lenvatinib Name of the medicinal product: Lenvima Apresentação (ões): 30 capsules with a dose of 4 mg, n.o de Titular da AIM: Eisai GmbH",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "The following information is provided by AVALIAÇÃO FARMACOTERAPÊUTICA:",
      "text": "The medicinal product Lenvima (lenvatinib) was subject to a public financing evaluation and the following indication therapeuuti treatment of adult patients with ressecable hepatocarcinoma, who have not received any treatment in comparison to sorafenib, or medicinal product evaluated for comparability.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Summary of the economic evaluation:",
      "text": "The cost of therapy with lenvima (lenvatinib) is the cost of therapy with sorafenib.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "1. Epidemiology and characterization of the disease",
      "text": "Hepatocellular carcinoma (CHC) is the primary tumor of the liver but most frequent, comprising about 90% of these tumors. It is the sixth most frequent in the world, being responsible for a large number of deaths. CHC occur in 90% of situations in the context of cirrhosis, being the main risk factors in no Western world, an infection by hepatitis C virus and alcoholism. No Eastern world has an elevated prevalence of hepatitis B (which is shown to have a direct effect on cognition).",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "2.Description of the technology and therapeutic alternatives",
      "text": "O lenvatinib is an inhibitor of multiple receptors of tyrosinaquinase (RTK) and selectively inhibits the activity of two receptors of vascular endothelial growth factor (VEGF), receptors of VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4), as well as other RTKs related to via pró-angiogénica e oncogénica, including receptors of fibroblast growth factor (FGF), receptors of FGFR1, 2, 3, and 4; or receptors of platelet growth factor (PDGF), receptors of PDGFRα, KIT and RET. As different therapeutic modalities are used: surgery, transplantation, thermo-transplantation and other therapeutic modalities are used, but 5% of the clinical doses are used to compare therapeutic methods used in the field of medicine.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Indicação/subpopulation Intervenção Comparador",
      "text": "1 Patients with advanced or non-resisable hepatocellular carcinoma lenvatinib sorafenib, who have not received any prior systemic therapy, aged ≥ 18 years Table 1  Subpopulations and comparators selected Terms of Comparison Other consideration T 3.2 Terms of Comparison Medicam in evaluations Medicam in evaluations Medicam in evaluations of a rare and Medicam in evaluation Comparison Table 2  Terms of treatment A daily recommended dose of lenvatinib is 8 mg (two capsules of 4 mg) once daily for patients with a body weight < 60 kg and 12 mg (three capsules of 4 mg) once daily for patients with a body weight < 60 kg.",
      "start_page": 4,
      "end_page": 6
    },
    {
      "heading": "The Commission shall adopt the measures referred to in paragraph 1 as follows:",
      "text": "Survivência Global crítico Survivência Livre de Progressão importante Tax de réponse importante Assessment of the quality of life critical",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "The Commission shall take the necessary measures to ensure that:",
      "text": "No de eventos adversos importantes Taxa de reacções adversas grau 3 e 4 Critical Mortalidade Related to critical treatment Taxa de abandono do estudo por toxicidade crítica Table 3  Medidas de Avaliação",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "5.Description of the studies evaluated",
      "text": "Study REFLECT (1) Comparative ensaios de no inferioridad, aberto, de fase 3, randomizado, multinacional comparing lenvatinib a sorafenib no treatment de primera línea de hacer posibilidad de ressección. Criteria de inclusion e exclusion Patients eligible had hepatocellular carcinoma irrespectable, either diagnostically or histologically, or confirmed clinically in accordance with the criteria of the Ass for the Study of Heat Diseases.",
      "start_page": 6,
      "end_page": 14
    },
    {
      "heading": "6. Evaluation of evidence by outcome",
      "text": "Survival Global A median for a global survival duration (OS) was of 13,6 months (IC95%: 12,114,9) for the 478 patients no group lenvatinib, compared with 12,3 months (IC95%: 10,4-13,9) for the 476 patients no group sorafenib (HR 0,92, IC 95%: 0,79-1,06  analysis in intention of treating (ITT)).",
      "start_page": 14,
      "end_page": 16
    },
    {
      "heading": "7. Qualidade da evidência submetida",
      "text": "The evidence submitted was classified as being of moderate quality for all the results, since there were some significant differences between some basic characteristics with potential impact on the forecast and de facto being an open study.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "8. evaluation and comments to evidence submitted",
      "text": "An analysis of the request for evaluation of the therapeutic value of lenvatinib in addition to an indication Monotherapy for the treatment of adult patients with advanced or non-ressectable CHC, who have not received any prior systemic therapeutics. An evidence submitted by the company refers to the REFLECT study which is a comparative trial of non-inferiority, open, of phase 3, randomized, multinational and multicentric, which compares lenvatinib to sorafenib no treatment of patients with HCC with the possibility of ressection.",
      "start_page": 17,
      "end_page": 18
    },
    {
      "heading": "9. Value therapeutic accentado",
      "text": "An analysis of the request for evaluation of the therapeutic value of lenvatinib in indication Monotherapy for the treatment of adult patients with advanced or non-resisable CHC who have not received any prior systemic therapeutics. It is concluded that there are indications of comparability of lenvatinib in comparison with lenfenib for the treatment of adult patients with advanced or non-resisable CHC. This conclusion is based on no:  REFLECT study that is a trial of non- inferiority, open, of phase 3, clinical, multinational and multiclinical, which demonstrates a random sampling of non-primary treatment with HCC.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "10. economic evaluation",
      "text": "For the purposes of paragraph (a) of point 8 of Decree Law No 97/2015, of 1 June, an economic advantage of the medicinal product in evaluation is 10% lower compared to its comparative alternative. Similarly, the medicinal product Lenvima presents a treatment cost 10% lower than the cost of treatment of the comparator sorafenib.",
      "start_page": 18,
      "end_page": 19
    },
    {
      "heading": "11. Conclusions",
      "text": "This conclusion is based on the following:  REFLECT study that is a comparative non inferiority, open, phase 3, randomized, multinational and multicentric study comparing lenvatinib to sorafenib for the first-line treatment of patients with HCC without the possibility of ressection.  No REFLECT study demonstrated no inferiority or superiority compared to sorafenib for overall survival, critical evaluation.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "12. Referências bibliográficas",
      "text": "(1)Kudo et al. (Lenvatinib versus sorafenib in first-lin\nhepatocellular carcinoma: a randomised phase 3 non-\nne treatment of patients with unresectable\n-inferiority trial. Lancet 2018; 391: 1163–73).",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading < none>",
      "text": "Row 1: 1 Row 2: ",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Table under the heading <RESUMO DA AVALIAÇÃO ECONÓMICA:>",
      "text": "Row 1: 2 Row 2: ",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Table under the heading <RESUMO DA AVALIAÇÃO ECONOMICA:> (column 1)",
      "text": "Row 1: Row 2: ",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Table under heading < 1. Epidemiologia e caracterização da doença>",
      "text": "Row 1: 3 Row 2: ",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "Table under the heading <Indicação/subpopulação Intervenção Comparador>",
      "text": "Row 1:Indicação população deve Intervenção/subpopulação deve Comparador Row 2: 1 Dozens with advanced hepatocellular carcinoma or not resectable, who have not received any prior systemic therapeutic treatment, e com age ≥ 18 years of age",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Table under the heading <Indicação/subpopulação Intervenção Comparador>",
      "text": "Row 1: 4 Row 2: ",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Table under the heading <Indicação/subpopulação Intervenção Comparador> (from previous page)",
      "text": "Line 1: Medicamento em avaliação Line 2: Medicamento comparador Line 3: Medicamento em avaliação Line 4: Medicamento comparador",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Table under the heading <Indicação/subpopulação Intervenção Comparador> (from previous page)",
      "text": "Row 1: 5 Row 2: ",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Table under the heading <Indicação/subpopulação Intervenção Comparador> (from previous page, column 1)",
      "text": "Row 1: Row 2: ",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados>",
      "text": "Row 1: Availability of evaluation in the course of the study: Row 1: Availability of evaluation in the course of the study: Row 2: Availability of evaluation in the course of the study: Row 3: Availability of evaluation in the course of the study: Row 3: Availability of evaluation in the course of the study: Row 5: Availability in the course of the study: Row 7: Availability in the course of the study: Row 8: Availability in the course of the study: Row 8: Availability in the course of the study: Row 9: Availability in the course of the study: Row 9: Availability in the course of the study: Row 10: Availability in the course of the study: Row 10: Availability in the course of the study: Row 10: Availability in the course of the study: Row 10: Availability in the course of the study:",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (column 1)",
      "text": "Row 1: Measures of evaluation of the quality of life in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the presence of the person in the person in the presence of the person in the presence of the person in the person in the presence of the person in the person in the presence of the person in the person in",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (column 2)",
      "text": "Row one: Row two: Row three:",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (column 2)",
      "text": "Row 1: |",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page)",
      "text": "Line 1: 7 Line 2: M-DATS-020/03",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page)",
      "text": "Line 1: 8 Line 2: M-DATS-020/03",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page)",
      "text": "Line 1: 9 Line 2: M-DATS-020/03",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page, column 2)",
      "text": "Row 1: Row 2: ",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page)",
      "text": "Line 1: 10 Line 2: M-DATS-020/03",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page, column 1)",
      "text": "Row 1: 1 Row 2: M",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page, column 19)",
      "text": "Row 1: Row 2: 03",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page)",
      "text": "Line 1: 11 Line 2: M-DATS-020/03",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page, column 1)",
      "text": "Line 1: 11 Line 2: M-DATS-02",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page, column 2)",
      "text": "Line 1: Line 2: 20/03",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page, column 3)",
      "text": "Row 1: Row 2: ",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page)",
      "text": "Line 1: 12 Line 2: M-DATS-020/03",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page)",
      "text": "Line 1: 13 Line 2: M-DATS-020/03",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "Table under heading <5. Descrição dos estudos avaliados> (from previous page, column 2)",
      "text": "Row 1: Row 2: ",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "Table under heading <6. Evaluation of evidence per outcome>",
      "text": "Line 1: 14 Line 2: M-DATS-020/03",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Table under heading <6. Evaluation of evidence per outcome> (from previous page)",
      "text": "Line 1: 15 Line 2: M-DATS-020/03",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Table under heading <6. Evaluation of evidence per outcome> (from previous page, column 2)",
      "text": "Row 1: Row 2: ",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Table under heading <7. Qualidade da evidência submetida>",
      "text": "Line 1: 16 Line 2: M-DATS-020/03",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Table under heading <8. Avaliação e comentários à evidência submetida>",
      "text": "Line 1: 17 Line 2: M-DATS-020/03",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Table under heading <10.",
      "text": "Line 1: 18 Line 2: M-DATS-020/03",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Table under heading < 11.",
      "text": "Line 1: 19 Line 2: M-DATS-020/03",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Table under heading <12. Referências bibliográficas>",
      "text": "Line 1: 20 Line 2: M-DATS-020/03",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Table under heading <12. Referências bibliográficas> (column 2)",
      "text": "Row 1: Row 2: ",
      "start_page": 20,
      "end_page": 20
    }
  ]
}